title: Anaphylactic events observed within 4 h of ocular application of an antibiotic-containing ophthalmic preparation: 61 cats (1993-2010).
abstract: This study describes signalment, history, antibiotic administered, clinical signs observed, therapy, and outcome of anaphylactic events within 4 h following ophthalmic administration of an antibiotic to cats. Data came from survey responses (45 cats) or Federal Drug Administration reports (16 cats). Cat age (7 weeks-19 years), breed, and gender ranged widely. Most were healthy (87%) prior to anaphylaxis. Ophthalmic antibiotics commonly were administered for conjunctival (65%) or corneal (11%) disease, or ocular lubrication (7%) and contained bacitracin, neomycin, and polymyxin B (44%), or oxytetracycline and polymyxin B (21%). Polymyxin B was present in all cases. Vaccines or other drugs were also administered to 51% of cats. In 56% cases, anaphylaxis occurred within 10 min of drug application. Most (82%) cats survived. Although a causal association was not proved, ophthalmic antibiotic administration preceded anaphylaxis in all cats. Like other drugs, ophthalmic antibiotics should be used only when indicated.
authors: Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, CA 95616, USA.
authors: Karen M
authors: KM
authors: Hume-Smith
authors: Allyson D
authors: AD
authors: Groth
authors: Mark
authors: M
authors: Rishniw
authors: Linda A
authors: LA
authors: Walter-Grimm
authors: Signe J
authors: SJ
authors: Plunkett
authors: David J
authors: DJ
authors: Maggs
mesh_terms: D060433:Administration, Ophthalmic / Q000662:veterinary; D000707:Anaphylaxis / Q000139:chemically induced / Q000453:epidemiology / Q000662:veterinary*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001414:Bacitracin / Q000008:administration & dosage; D002371:Cat Diseases / Q000188:drug therapy* / Q000453:epidemiology* / Q000473:pathology; D002415:Cats; D003320:Corneal Ulcer / Q000188:drug therapy / Q000662:veterinary*; D005260:Female; D008297:Male; D009355:Neomycin / Q000008:administration & dosage; D009883:Ophthalmic Solutions / Q000008:administration & dosage* / Q000009:adverse effects; D010118:Oxytetracycline / Q000008:administration & dosage; D011112:Polymyxin B / Q000008:administration & dosage; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
chemical_list: D000900:Anti-Bacterial Agents; D009883:Ophthalmic Solutions; D001414:Bacitracin; D009355:Neomycin; D011112:Polymyxin B; D010118:Oxytetracycline